ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI
https://abvcpharma.com/wp-content/themes/movedo/images/empty/thumbnail.jpg
150
150
Press Release
https://secure.gravatar.com/avatar/16e1fb99bcbeb5306557b18c84c6454051e7fb0924dd51867e73dc4cd6833b54?s=96&d=mm&r=g
FREMONT, CA – July 9, 2024 – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that after successful Phase II clinical trials of their medication…
read more